Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part D introduced by the Inflation Reduction Act (IRA) that took effect in 2025, annual out-of-pocket drug costs for all beneficiaries are now capped at $2,000. However, an overlooked voluntary program that’s part of the IRA could be the key to improving affordability for Medicare patients needing expensive oral cancer drugs, according to a new study from researchers from the Perelman School of Medicine at the University of Pennsylvania published today in JCO Oncology Practice.

The National Foundation for Cancer Research (NFCR) proudly congratulates Dr. Robert C. Bast, Jr., a pioneering cancer scientist, and NFCR-supported investigator from 2001 to 2018, on being named the 2025 recipient of the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research

A recent global survey of 156 institutions reveals strong interest in VR-haptic technology for dental training, yet significant barriers impede widespread adoption.

Researchers at Aston University have called for more advice to be given to young people about preventing dry eye disease, after a study carried out in conjunction with Oslo University Hospital and Sørlandet Hospital Trust in Norway found that 90% of participants had at least one sign of the condition in their eyes.